Leap Therapeutics Inc (OQ:LPTX)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 47 Thorndike St Ste B1-1
CAMBRIDGE MA 02141-1799
Tel: N/A
Website: https://www.leaptx.com
IR: See website
Key People
Business Overview
Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Financial Overview
For the fiscal year ended 31 December 2018, Leap Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders excluding extraordinary items decreased 44% to $23.1M. Lower net loss reflects Interest income increase from $170K to $447K (income), Interest expense - related party decrease from $121K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$4.50 to -$1.64.
Employees: 23 as of Mar 26, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $22.23M as of Dec 31, 2018
Annual revenue (TTM): $0.00M as of Dec 31, 2018
EBITDA (TTM): -$30.70M as of Dec 31, 2018
Net annual income (TTM): -$23.14M as of Dec 31, 2018
Free cash flow (TTM): -$26.03M as of Dec 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 22,260,301 as of Mar 26, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization